Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...

In May, it announced it would acquire SiteOne Therapeutics, a drugmaker with a promising investigational medicine for pain. In January, it grew its oncology pipeline through the acquisition of a ...

Eli Lilly stock dips despite strong Q2 results. Read my insights on obesity drug market dominance and why this selloff in LLY may be a buying opportunity.

Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q2 2025 Earnings Conference Call. [Operator Instructions] I would now like to turn the […] ...

Revenue in Q2 2025 increased 38% to $15.56 billion driven by volume growth from Zepbound and Mounjaro. <li /> Increased the midpoint of ...

Eli Lilly and Company’s LLY stock has declined 5.1% so far this month, despite announcing strong second-quarter results on ...

In vivo CAR T-cell therapies promise to revolutionize cancer treatment, enhancing access and reducing costs while addressing ...

The drug, based on Nobel Prize-winning gene-editing technology CRISPR-Cas9, reaches the liver cells and splices out the ...

Eli Lilly Shares Plummet 14% Toward Worst Day In 25 Years—Here’s Why It’s Down By Ty Roush, Forbes Staff. Ty Roush is a breaking news reporter based in New York City.

LTZ Therapeutics (“LTZ”), an immunotherapy-focused biotechnology company, today announced a strategic research collaboration with Eli Lilly and Company (“Lilly”) to develop novel myeloid ...

Eli Lilly is pivoting its pain pipeline, punting a midstage program it licensed from Centrexion Therapeutics while adding a candidate from its recent SiteOne Therapeutics buyout to its early-phase ...

Verve Therapeutics, Inc. (NASDAQ:VERV) is one of the Stocks With Huge Catalysts on the Horizon. On April 14, Verve Therapeutics, Inc.